The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Recainam     3-(2,6-dimethylphenyl)-1-[3- (propan-2...

Synonyms: Recainamum, CHEMBL551786, SureCN636093, Wy-42362, LS-177147, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Recainam

  • Recainam, a potent new antiarrhythmic agent: effects on complex ventricular arrhythmias [1].
  • The antiarrhythmic efficacy and safety of intravenous recainam, a newly synthesized compound displaying potent class I antiarrhythmic activity, were tested in 10 hospitalized patients with frequent (greater than 30/h) complex ventricular ectopic beats [1].
  • Electrophysiologic effects and efficacy of recainam for sustained ventricular tachycardia [2].
  • Recainam was administered as a loading dose of 3 mg/kg/40 minutes followed by a continuous infusion of 0.9 mg/kg/hr for 23 hours and 20 minutes to ten patients with cardiac disease and frequent PVCs (more than 30/hr) [3].
  • Based on these data, recainam can be safely administered as a loading dose followed by a continuous infusion in patients with stable cardiac disease without significant ventricular dysfunction [3].

High impact information on Recainam

  • The data indicate that the electrophysiologic profile of recainam in isolated cardiac muscle is consistent with the overall effects of class IC agents without having an effect on the slow calcium channel [4].
  • Recainam induced a concentration- and frequency-dependent decrease in the maximal rate of rise of the phase 0 of the action potential (Vmax), action potential amplitude and overshoot potential, with little or no change in the effective refractory period except in Purkinje fibers, in which it was markedly reduced [4].
  • OBJECTIVES: To investigate the pharmacokinetics and pharmacodynamics of recainam, an investigational class I antiarrhythmic agent, in subjects with various degrees of renal function [5].
  • Recainam (100 microM) reduced IK by only 7 (SEM 3)% after 20-30 min exposure and by 19% after an 80 min exposure (IC50 > 400 microM) [6].
  • The absolute bioavailability of orally administered recainam increased from 73% for the 200 mg dose to 81% and 84% for the 400 and 800 mg doses, respectively [7].

Chemical compound and disease context of Recainam


Biological context of Recainam

  • Cardiac electrophysiology of the antiarrhythmic agent recainam (Wy-42,362) in anesthetized dogs: relation to plasma and myocardial concentrations [10].
  • The results showed no change in mean arterial pressure, but heart rate increased slightly by 4 beats/min following recainam infusion [11].
  • The curves relating membrane potential and Vmax in preparations stimulated at a low frequency (0.01 Hz) were not shifted by 10(-4) M recainam [12].
  • The plasma Cmax and AUC of recainam were virtually identical after single or multiple (21 day) oral doses in dogs [13].

Anatomical context of Recainam


Associations of Recainam with other chemical compounds


Analytical, diagnostic and therapeutic context of Recainam


  1. Recainam, a potent new antiarrhythmic agent: effects on complex ventricular arrhythmias. Anastasiou-Nana, M.I., Anderson, J.L., Hampton, E.M., Nanas, J.N., Heath, B.M. J. Am. Coll. Cardiol. (1986) [Pubmed]
  2. Electrophysiologic effects and efficacy of recainam for sustained ventricular tachycardia. de Buitleir, M., Kou, W.H., Nelson, S.D., Schmaltz, S., Morady, F. Am. J. Cardiol. (1989) [Pubmed]
  3. The disposition of recainam hydrochloride during and after intravenous loading and maintenance infusion in cardiac patients. Hampton, E.M., Anastasiou-Nana, M.I., Nanas, J.N., Nappi, J.M., Capuzzi, D.M., Anderson, J.L. Journal of clinical pharmacology. (1987) [Pubmed]
  4. Electrophysiologic effects of a new antiarrhythmic agent, recainam, on isolated canine and rabbit myocardial fibers. Takikawa, R., Kamiya, K., Kato, R., Singh, B.N. J. Am. Coll. Cardiol. (1988) [Pubmed]
  5. Effects of renal function on recainam pharmacokinetics and pharmacodynamics. Cheng, J.W., Charland, S.L., Goldfarb, S., Spinler, S.A. Clin. Pharmacol. Ther. (1995) [Pubmed]
  6. Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: evidence for open channel block and unblock. Follmer, C.H., Cullinan, C.A., Colatsky, T.J. Cardiovasc. Res. (1992) [Pubmed]
  7. The absolute bioavailability and dose proportionality of intravenous and oral dosage regimens of recainam. Troy, S.M., Cevallos, W.H., Conrad, K.A., Chiang, S.T., Latts, J.R. Journal of clinical pharmacology. (1991) [Pubmed]
  8. Efficacy of recainam, a new antiarrhythmic drug, for control of ventricular arrhythmias. Anderson, J.L., Anastasiou-Nana, M.I., Heath, B.M., Menlove, R.L., Nanas, J.N., Friedman, J. Am. J. Cardiol. (1987) [Pubmed]
  9. Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction. Feld, G.K., Venkatesh, N., Singh, B.N. J. Cardiovasc. Pharmacol. (1988) [Pubmed]
  10. Cardiac electrophysiology of the antiarrhythmic agent recainam (Wy-42,362) in anesthetized dogs: relation to plasma and myocardial concentrations. Colatsky, T.J., Bird, L.B., Knowles, J.A. J. Cardiovasc. Pharmacol. (1988) [Pubmed]
  11. Clinical electrophysiological effects of intravenous recainam: an antiarrhythmic drug under investigation for the treatment of ventricular and supraventricular arrhythmias. Feld, G.K., Luceri, R.M., Greenspon, A.J., Singh, B.N., Horowitz, L.N., Capuzzi, D.M., Frame, V.B., Myerburg, R.J. Pacing and clinical electrophysiology : PACE. (1991) [Pubmed]
  12. Frequency- and voltage-dependent effects of recainam on the upstroke velocity of action potential in rabbit ventricular muscle. Kamiya, K., Takikawa, R., Singh, B.N. J. Cardiovasc. Pharmacol. (1989) [Pubmed]
  13. Species differences in the pharmacokinetics of recainam, a new anti-arrhythmic drug. Scatina, J.A., Kimmel, H.B., Weinstein, V., Troy, S.M., Sisenwine, S.F., Cayen, M.N. Biopharmaceutics & drug disposition. (1990) [Pubmed]
  14. Effect of recainam on the energy required for ventricular defibrillation in dogs as assessed with implanted electrodes. Frame, L.H., Sheldon, J.H. J. Am. Coll. Cardiol. (1988) [Pubmed]
  15. Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias. Davies, R.F., Lineberry, M.D., Funck-Brentano, C., Echt, D.S., Lee, J.T., Capuzzi, D.M., Roden, D.M., Woosley, R.L. Clin. Pharmacol. Ther. (1989) [Pubmed]
WikiGenes - Universities